Currently, trials are being conducted to test potential inhibitors of some receptor tyrosine kinases such as HER2, hepatocyte growth factor receptor (MET), fibroblast growth factor receptor (FGFR2), and epidermal growth factor receptor (EGFR) that are overexpressed in CIN GC (Table 1) [9,30]. Here, ERBB2 is linked to gastric cancer.